Glenn Pierce

[Glenn Pierce @gfp55]

@wfhemophilia Victor was a major force for patients and health care providers in many countries around the world. His vision will be greatly
missed but the good he has done remains for all.

[WFH @wfhemophilia]

🚨 Time's running out to submit your #BleedingDisorders research to the #WFHCongress2024! Don't miss this opportunity to showcase your work on a global stage, win prestigious awards, and connect with global experts. Deadline: Nov 15, 2023. Submit now:https://t.co/lIzneA35Ei 🩸

[Glenn Pierce @gfp55]

World Federation of Hemophilia (@wfhemophilia) and (@EHC_Haemophilia) statement on vaccine thrombosis thrombocytopenia. Persons with bleeding disorders not at increased risk from very rare event, should get vaccinated. Risks of COVID-19 greater https://t.co/NyK6lY0NaX

[Glenn Pierce @gfp55]

Come watch the arguments, assessments and suggestions for evaluating gene therapies for hemophilia

[WFH @wfhemophilia]

On Dec 11 at 10 a.m. the WFH will host a session to explore patient perspectives related to the scientific inquiry of gene therapy. The panelists will discuss the quest to answer the unknowns around safety, variability and durability of response. Register: https://t.co/hkxW49wk2C

[Glenn Pierce @gfp55]

@wfhemophilia Congratulations Steve. Well deserved!

[WFH @wfhemophilia]

The #WFHVirtualSummit Committee understands the importance of sharing knowledge of #VWD and the Summit program reflects this. Glenn Pierce, MD, PhD, WFH Vice-President, Medical, highlights the importance of bringing awareness to VWD. Watch the video here: https://t.co/pmlq7cWXst

[Glenn Pierce @gfp55]

https://t.co/1h21ag86Eb

[Glenn Pierce @gfp55]

The High Price of Hemophilia https://t.co/CcE2z1B6iN via @ASH Clinical News

[Glenn Pierce @gfp55]

The hemophilia gene therapy race faces a critical year in 2020 https://t.co/j1T3G1wgjG via @BioPharmaDive

[Glenn Pierce @gfp55]

@thehill This picture says it all

[Glenn Pierce @gfp55]

@ProfMakris This appears to support the Iorio-Stonebraker Ann Int Med data based upon complete reporting in 6 countries

[Glenn Pierce @gfp55]

assuming specific activity of the transgene protein is same as pd or recombinant. Ag levels are not the solution unless specific activity is previously validated.

[Michael Makris @ProfMakris]

At least they can be compared properly with antigen estimation?

[Glenn Pierce @gfp55]

@Brianhaemophil1 @NHF_Hemophilia @HaemophiliaIRL This recombinant FX manufactured to treat hemA and hemB dogs who have inhibitors. Effective replacement to manage dogs

[WFH @wfhemophilia]

The WFH WBDR has reached another milestone – over 2,500 patients! We are well on our way to our goal of enrolling 10,000 patients #patientvoice.The WFH would like to thank everyone involved for helping us to grow the WBDR #bleedingdisorders #hemophilia https://t.co/opUeL4zEUz

[WFH @wfhemophilia]

Join us at #WFH2020WorldCongress for the largest congress for the #bleedingdisorders community! While there, take the time to explore the Batu Caves, said to be around 400 million years old. https://t.co/AejeRbpwUe #TreatmentforAll

[Glenn Pierce @gfp55]

Bayer Makes Global Impact Through World Federation of Hemophilia Humanitarian Aid Program | BioSpace https://t.co/5o2C0ZvJtp #jobs

[Glenn Pierce @gfp55]

St. Jude Children’s Research Hospital and the World Federation of Hemophilia announce collaboration
New arrangement will establish gene therapy clinical trial for hemophilia patients in low- and middle-income countries

https://t.co/YBI5QgRe0y #genetherapy #WorldHemophiliaDay2019

[Glenn Pierce @gfp55]

April 17 is the day!

[WFH @wfhemophilia]

This #WorldHemophiliaDay, Boston will stand out again as 2 of its most famous landmarks will #LightItUpRed. Can you guess which ones? #WHD2019

[Glenn Pierce @gfp55]

@DevinNunes You requested money from me. You are a Trump stooge. Ask him for money

[Sanofi @sanofi]

We are pleased to announce our acquisition of @Bioverativ, a biopharma company focused on therapies for hemophilia and other rare blood disorders, expanding our presence in specialty care and strengthening our leadership in rare diseases #Bioverativ https://t.co/BDraaabnDf